Moreover, administration of recombinant ISM1 could inhibit glioma growth by anti-angiogenesis with no significant side effects, which further proved the anti-angiogenic ability of ISM1(Xiang et al. 2011; Yuan et al. 2012). Here, ISM1 is linked to central nervous system cancer.